Gip vs GLP-1
You are deciding between two options.
Reference and calculator, not medical advice. Dosing figures below are transcribed from FDA-approved prescribing information and link back to it. Last reviewed August 2026.
GIP is not a competitor to GLP-1 and not a higher-numbered version of it. It is a separate incretin hormone from a different precursor entirely, and the reason it comes up is that one medication targets both at once.
What GIP actually is
Glucose-dependent insulinotropic polypeptide — a separate incretin hormone, not part of the proglucagon family at all.
- FDA-approved medication
- Yes
- Approved for
- No GIP-only medication is marketed. GIP is targeted alongside GLP-1 by tirzepatide.
- Example
- Tirzepatide (Zepbound, Mounjaro) is a dual GIP and GLP-1 receptor agonist
- Difference that matters
- Not an alternative to GLP-1 but a second target hit at the same time. The Zepbound label describes tirzepatide as "a GIP receptor and GLP-1 receptor agonist".
This page describes what each thing is and what it is approved for. It does not compare how well they work, because that is a question for a prescriber with your history in front of them.
The Zepbound label states it directly: tirzepatide "is a GIP receptor and GLP-1 receptor agonist" and "selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1". On what GIP adds, the label is deliberately cautious — it says nonclinical studies suggest the addition of GIP may further contribute to the regulation of food intake. That is a hedged statement about animal data, not a claim of superiority, and it is the manufacturer writing about its own product.
Side-by-side
Structural facts from each product’s prescribing information.
| Product | Active ingredient | Indication | Frequency | Start | Max labelled | Steps to max |
|---|---|---|---|---|---|---|
| Zepbound Eli Lilly | Tirzepatide | Weight management | Weekly | 2.5 mg | 15 mg | 6 |
| Wegovy Novo Nordisk | Semaglutide | Weight management | Weekly | 0.25 mg | 2.4 mg | 5 |
Note the doses in that table are on completely different scales. Tirzepatide runs to 15 mg and semaglutide injection to 2.4 mg, which reflects different molecules rather than different strengths. Comparing the numbers directly is meaningless.
Common questions
- Is a GIP-only drug available?
- No GIP-only medication is marketed. GIP appears in approved treatment only alongside GLP-1, in tirzepatide.
- Does targeting both make it better?
- Not a question this site answers. What the label supports is that tirzepatide targets both receptors and that the contribution of GIP is described from nonclinical studies in hedged terms.
- Is GIP part of the GLP family?
- No. GLP-1 and GLP-2 come from proglucagon. GIP is a separate hormone with its own precursor and its own receptor. It sits in the same functional group — incretins — which is why it is discussed alongside them.
Sources and last review
Every dosing figure on this page is transcribed from an FDA-approved label and links back to it. Conversions are arithmetic you can repeat by hand. Nothing here is reviewed by a clinician, and this site does not employ one — which is exactly why what I do publish stays traceable to its source.
- Zepbound (Tirzepatide) prescribing information — Eli Lilly, label revised 6 May 2026, checked 7 August 2026
- Wegovy (Semaglutide) prescribing information — Novo Nordisk, label revised 30 June 2026, checked 7 August 2026
Transcribed from the labels above and checked by me — Gavin, who builds this site, takes a GLP-1, and is not a clinician. Last reviewed August 2026. Found an error? [email protected] — I treat corrections as bugs. How this site is built and funded.
Also searched as: glp 1 vs gip · glp-1 vs gip · glp-1 vs glp-1/gip · glp 1 vs glp 1 gip